Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel

CD19‐directed chimeric antigen receptor T lymphocytes (CAR‐T) have led to durable remissions in children with refractory and/or multiply relapsed B‐lymphoblastic leukemia. For those who relapse or lose B‐cell aplasia post CAR‐T, the role of CAR‐T reinfusion is unclear. We report two cases of durable...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2023-05, Vol.70 (5), p.e30271-n/a
Hauptverfasser:	Galletta, Thomas J., Rubinstein, Jeremy D., Krupski, Christa, Nelson, Adam S., Khoury, Ruby, Dandoy, Christopher E., Davies, Stella M., Phillips, Christine L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptor Proteins, Signal Transducing Antigens, CD19 Aplasia B‐cell aplasia B‐lymphoblastic leukemia CAR‐T CD19 antigen Child Chimeric antigen receptors CTL019 Hematology Humans Immunotherapy, Adoptive Lymphatic leukemia Lymphocytes T Oncology Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Antigen, T-Cell - therapeutic use Receptors, Chimeric Antigen reinfusion Remission Remission Induction tisagenlecleucel
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!